modelInterferonGamma
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB03.
Information
| name: | InterferonGamma | |
| ATC code: | L03AB03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.12 | L |
| clearance: | 277 | mL/min |
| other parameters in model implementation | ||
Interferon gamma (IFN-γ) is a cytokine produced by lymphocytes, especially T-lymphocytes and natural killer cells, and is involved in innate and adaptive immunity. Recombinant human interferon gamma is used as an immunomodulatory agent in the treatment of chronic granulomatous disease and severe malignant osteopetrosis. It is approved for use in certain immune deficiencies and is not typically used in standard antiviral therapy.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after a single intravenous dose of recombinant human interferon gamma.
References
Wlodek, E, et al., & Devey, L (2021). A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PloS one 16(3) e0247972–None. DOI:10.1371/journal.pone.0247972 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33684160
Ellis, J, et al., & Fernando, D (2019). Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. British journal of clinical pharmacology 85(2) 304–315. DOI:10.1111/bcp.13748 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30161291
Wingender, G, et al., & Knolle, PA (2006). Rapid and preferential distribution of blood-borne alphaCD3epsilonAb to the liver is followed by local stimulation of T cells and natural killer T cells. Immunology 117(1) 117–126. DOI:10.1111/j.1365-2567.2005.02272.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16423047
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)